Factors Influencing Patient Decision-Making in the Treatment of Muscle-Invasive Bladder Cancer

Overview

Journal Bladder Cancer

Publisher IOS Press

Date 2024 Aug 12

PMID 39131874

Authors

Avani Desai

Lucas Bouknight

Thomas Reed

Dana Mueller

Chelsea Osterman

Michael Repka

Tracy Rose

Angela B Smith

Affiliations

Soon will be listed here.

Abstract

Background: In 2023, an estimated 82,290 individuals were diagnosed with bladder cancer in the United States. For muscle-invasive bladder cancer (MIBC), the American Urological Association recommends offering radical cystectomy with cisplatin-based neoadjuvant chemotherapy. However, patients are increasingly requesting alternative treatments.

Objective: To describe factors influencing selection of radical cystectomy with cisplatin-based neoadjuvant chemotherapy (NAC + RC), radical cystectomy monotherapy (RC), or tri-modality therapy (TMT) among patients with MIBC.

Methods: Individual, semi-structured phone interviews were conducted with 18 adults who underwent MIBC treatment at the University of North Carolina, recruiting six patients each from three treatment groups: 1) NAC + RC, 2) RC, and 3) TMT. Interview transcriptions were qualitatively analyzed using QSR NVivo, with major themes and sub-themes extracted. Patients also completed the Shared Decision-Making Questionnaire (SDM-Q-9; range 0-100).

Results: Concern for survival and risks, quality of life, and varied patient preferences for involvement influenced the decision-making process. Concern surrounding sexual function, bladder preservation, and urostomy bags drove patients towards TMT. High levels of shared decision-making were observed overall, with a median SDM-Q-9 score of 95 (IQR 89-100). Patients undergoing TMT reported the highest median SDM-Q-9 score (97, IQR 94-100), while those receiving radical cystectomy alone had the lowest (66, IQR 37-96).

Conclusions: Patients with MIBC described a multifaceted treatment decision-making process, highlighting key influences, concerns, and unmet needs. Understanding this process can help address misconceptions and align treatment choices with patient goals. Physicians can use these insights to engage in shared decision-making, ultimately improving patient experiences and outcomes.

References

Budenbender B, Kother A, Kriegmair M, Grune B, Michel M, Alpers G . Getting specific: participation preference in urooncological decision-making. BMC Med Inform Decis Mak. 2023; 23(1):114. PMC: 10324222. DOI: 10.1186/s12911-023-02201-8. View

Chapple A, Ziebland S, Herxheimer A, McPherson A, Shepperd S, Miller R . Is 'watchful waiting' a real choice for men with prostate cancer? A qualitative study. BJU Int. 2002; 90(3):257-64. DOI: 10.1046/j.1464-410x.2002.02846.x. View

Zlotta A, Ballas L, Niemierko A, Lajkosz K, Kuk C, Miranda G . Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis. Lancet Oncol. 2023; 24(6):669-681. DOI: 10.1016/S1470-2045(23)00170-5. View

Verghote F, Van Praet C, Berquin C, Lumen N, Decaestecker K, Vanneste B . Radical cystectomy or trimodality therapy for muscle-invasive bladder cancer: a qualitative study exploring patient priorities and counselling needs when making a treatment choice. BMC Cancer. 2024; 24(1):160. PMC: 10832089. DOI: 10.1186/s12885-024-11927-1. View

Costin M, Makaroff L . Bladder Preservation With Radiotherapy: The Patient Perspective. Clin Oncol (R Coll Radiol). 2021; 33(6):346-349. DOI: 10.1016/j.clon.2021.03.015. View

Chalfant V, Blute Jr M, Silberstein P . Treatment trends of muscle invasive bladder cancer: Evidence from the Surveillance, Epidemiology, and End Results database, 1988 to 2013. Asian J Urol. 2023; 10(1):9-18. PMC: 9875153. DOI: 10.1016/j.ajur.2021.10.002. View

Smith A, Rincones O, Sidhom M, Mancuso P, Wong K, Berry M . Robot or radiation? A qualitative study of the decision support needs of men with localised prostate cancer choosing between robotic prostatectomy and radiotherapy treatment. Patient Educ Couns. 2019; 102(7):1364-1372. DOI: 10.1016/j.pec.2019.02.017. View

Garg T, Connors J, Ladd I, Bogaczyk T, Larson S . Defining Priorities to Improve Patient Experience in Non-Muscle Invasive Bladder Cancer. Bladder Cancer. 2018; 4(1):121-128. PMC: 5798497. DOI: 10.3233/BLC-170138. View

Yang L, Shan B, Shan L, Chin P, Murray S, Ahmadi N . A systematic review and meta-analysis of quality of life outcomes after radical cystectomy for bladder cancer. Surg Oncol. 2016; 25(3):281-97. DOI: 10.1016/j.suronc.2016.05.027. View

10.

Elwyn G, Frosch D, Thomson R, Joseph-Williams N, Lloyd A, Kinnersley P . Shared decision making: a model for clinical practice. J Gen Intern Med. 2012; 27(10):1361-7. PMC: 3445676. DOI: 10.1007/s11606-012-2077-6. View

11.

Chang S, Bochner B, Chou R, Dreicer R, Kamat A, Lerner S . Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline. J Urol. 2017; 198(3):552-559. PMC: 5626446. DOI: 10.1016/j.juro.2017.04.086. View

12.

Berry D, Ellis W, Woods N, Schwien C, Mullen K, Yang C . Treatment decision-making by men with localized prostate cancer: the influence of personal factors. Urol Oncol. 2003; 21(2):93-100. DOI: 10.1016/s1078-1439(02)00209-0. View

13.

Giacalone N, Shipley W, Clayman R, Niemierko A, Drumm M, Heney N . Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol. 2017; 71(6):952-960. DOI: 10.1016/j.eururo.2016.12.020. View

14.

Koo K, Zubkoff L, Sirovich B, Goodney P, Robertson D, Seigne J . The Burden of Cystoscopic Bladder Cancer Surveillance: Anxiety, Discomfort, and Patient Preferences for Decision Making. Urology. 2017; 108:122-128. PMC: 5626609. DOI: 10.1016/j.urology.2017.07.016. View

15.

Klein G, Ajay D, Volk R, Leal V, Westney O . Living With Urinary Diversions: Patient Insights to Improve the Perioperative Experience. Urology. 2021; 152:190-194. PMC: 8195837. DOI: 10.1016/j.urology.2021.01.009. View

16.

Kamat A, Hahn N, Efstathiou J, Lerner S, Malmstrom P, Choi W . Bladder cancer. Lancet. 2016; 388(10061):2796-2810. DOI: 10.1016/S0140-6736(16)30512-8. View

17.

Kriston L, Scholl I, Holzel L, Simon D, Loh A, Harter M . The 9-item Shared Decision Making Questionnaire (SDM-Q-9). Development and psychometric properties in a primary care sample. Patient Educ Couns. 2009; 80(1):94-9. DOI: 10.1016/j.pec.2009.09.034. View

18.

Check D, Leo M, Banegas M, Bulkley J, Danforth K, Gilbert S . Decision Regret Related to Urinary Diversion Choice among Patients Treated with Cystectomy. J Urol. 2019; 203(1):159-163. DOI: 10.1097/JU.0000000000000512. View

19.

Arcangeli G, Strigari L, Arcangeli S . Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: A systematic review of clinical trials. Crit Rev Oncol Hematol. 2015; 95(3):387-96. DOI: 10.1016/j.critrevonc.2015.04.006. View

20.

Pozzar R, Berry D . Gender Differences in Bladder Cancer Treatment Decision Making. Oncol Nurs Forum. 2017; 44(2):204-209. DOI: 10.1188/17.ONF.204-209. View